{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:38:09Z","timestamp":1762868289563,"version":"3.44.0"},"reference-count":17,"publisher":"BMJ","issue":"8","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2020,7,14]]},"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:p>Anaplastic lymphoma kinase-positive large B-cell lymphoma (ALK+ LBCL) is known to be a rare and aggressive form of lymphoma that relapses quickly after both conventional chemotherapy and more targeted therapy. Lenalidomide is an immunomodulator that has shown safety and efficacy in multiple myeloma and is also approved for use in several types of lymphoma. In the case described here, the patient had a significant partial response to lenalidomide, which has not previously been described in this type of lymphoma. Given how aggressive and difficult to treat ALK+ LBCL is, further research is warranted to more completely elucidate the mechanism of action of lenalidomide in ALK+ LBCL\u2009and its role in treatment.<\/jats:p>","DOI":"10.1136\/bcr-2020-235578","type":"journal-article","created":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T01:35:29Z","timestamp":1598405729000},"page":"e235578","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Lenalidomide demonstrates clinical activity in anaplastic lymphoma kinase-positive large B-cell lymphoma"],"prefix":"10.1136","volume":"13","author":[{"given":"Shakthi","family":"Bhaskar","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brooj","family":"Abro","sequence":"additional","affiliation":[{"name":"Department of Pathology, Washington University School of Medicine, St. Louis, Missouri, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tyler J","family":"Fraum","sequence":"additional","affiliation":[{"name":"Department of Radiology, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neha","family":"Mehta-Shah","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2020,8,25]]},"reference":[{"key":"2025082709255909000_13.8.e235578.1","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1182\/blood.V89.5.1483","article-title":"A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2; 5 translocation","volume":"89","author":"Delsol","year":"1997","journal-title":"Blood"},{"key":"2025082709255909000_13.8.e235578.2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/PAS.0000000000000753","article-title":"Alk-Positive large B-cell lymphoma: a clinicopathologic study of 26 cases with review of additional 108 cases in the literature","volume":"41","author":"Pan","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"2025082709255909000_13.8.e235578.3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0178416","article-title":"Anaplastic lymphoma kinase-positive large B-cell lymphoma: clinico-pathological study of 17 cases with review of literature","volume":"12","author":"Jiang","year":"2017","journal-title":"PLoS One"},{"key":"2025082709255909000_13.8.e235578.4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.5020"},{"key":"2025082709255909000_13.8.e235578.5","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26135"},{"key":"2025082709255909000_13.8.e235578.6","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq626"},{"key":"2025082709255909000_13.8.e235578.7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07728.x"},{"key":"2025082709255909000_13.8.e235578.8","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12240"},{"key":"2025082709255909000_13.8.e235578.9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-032987"},{"key":"2025082709255909000_13.8.e235578.10","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24175"},{"key":"2025082709255909000_13.8.e235578.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070594"},{"key":"2025082709255909000_13.8.e235578.12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.3429"},{"key":"2025082709255909000_13.8.e235578.13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-11-567792"},{"key":"2025082709255909000_13.8.e235578.14","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1016\/S2352-3026(15)00284-7","article-title":"Lenalidomide in relapsed adult T-cell leukaemia-lymphoma or peripheral T-cell lymphoma (ATLL-001): a phase 1, multicentre, dose-escalation study","volume":"3","author":"Ogura","year":"2016","journal-title":"Lancet Haematol"},{"key":"2025082709255909000_13.8.e235578.15","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001158"},{"key":"2025082709255909000_13.8.e235578.16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.2835"},{"key":"2025082709255909000_13.8.e235578.17","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.19.00010","article-title":"Augment: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma","volume":"37","author":"Leonard","year":"2019","journal-title":"J Clin Oncol"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2020-235578","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T16:26:10Z","timestamp":1756311970000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2020-235578"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":17,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,8,25]]},"published-print":{"date-parts":[[2020,8]]}},"alternative-id":["10.1136\/bcr-2020-235578"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2020-235578","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2020,8]]}}}